Sterling Research Group
Cardiology
Dr. Eli M. Roth, MD
|
|
Give Review
Eli M. Roth works in the field of Cardiology. He researched medicine at University Hospital - University of Cincinnati College of Medicine. He has 1 awards "Fellow (FACC)". Doctor Eli M. Roth, MD is a published doctor as well. He has 20 publications published. The latest was: Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 r...
Publications
- Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
- Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dos...
- Alirocumab for Hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia.
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled anal...
- A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglycerid...
- Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
- Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a ...
- Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
- The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
- Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridem...
- Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
- Fish oil for primary and secondary prevention of coronary heart disease.
- Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
- Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
- Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Eva...
- Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 r...
- ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
- Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study.
Schools
University of Cincinnati Main Campus
Christ Hospital
University Hospital
Conditions Treated
- Hyperlipidemia
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
University Hospital - University of Cincinnati College of Medicine -
University of Cincinnati College of Medicine
Hospital
-
Christ Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Fausto P. Vasquez, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy Brennan, MD |
|
|
Dr. James N. Muth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter H. Herzog, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen J. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nasrien E. Ibrahim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dia Smiley, DO |
|
|
Dr. Gary Webb, MD |